DCM
RARE icon

Driehaus Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Driehaus Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-603,397
Closed -$18.2M – 469
2025
Q3 		$18.2M Sell
603,397
-3,010
-0.5% -$90.3K 0.13% 214
2025
Q2 		$22M Sell
606,407
-246,250
-29% -$8.88M 0.18% 167
2025
Q1 		$30.9M Buy
852,657
+23,192
+3% +$965K 0.3% 108
2024
Q4 		$34.9M Buy
829,465
+45,521
+6% +$2.26M 0.29% 113
2024
Q3 		$43.5M Buy
783,944
+255,764
+48% +$13M 0.37% 91
2024
Q2 		$21.7M Buy
528,180
+138,889
+36% +$5.93M 0.21% 141
2024
Q1 		$18.2M Buy
389,291
+30,125
+8% +$1.42M 0.18% 167
2023
Q4 		$17.2M Buy
359,166
+137,920
+62% +$5.35M 0.21% 157
2023
Q3 		$7.89M Sell
221,246
-108,422
-33% -$4.3M 0.1% 238
2023
Q2 		$15.2M Buy
+329,668
New +$15.3M 0.19% 167
2014
Q4 		– Sell
-61,146
Closed -$3.46M – 565
2014
Q3 		$3.46M Sell
61,146
-30,729
-33% -$1.55M 0.13% 209
2014
Q2 		$4.12M Buy
91,875
+29,921
+48% +$1.23M 0.13% 214
2014
Q1 		$3.03M Buy
+61,954
New +$3.19M 0.1% 259

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Driehaus Capital Management's RARE Position: Q4 2025 in Review

Driehaus Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 603,397 shares — an estimated $18.2M sold.

Driehaus Capital Management first reported a position in RARE in Q1 2014 and held it in 13 quarters. The position peaked at $43.5M in Q3 2024. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

  • Driehaus Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Driehaus Capital Management sold 603,397 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $18.2M.
  • Driehaus Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and held it in 13 quarters.
  • Driehaus Capital Management's Ultragenyx Pharmaceutical position peaked at $43.5M in Q3 2024.
  • 287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Driehaus Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.